Exciting Developments in Relapsed/Refractory Multiple Myeloma

Opinion
Video

The panel concludes the discussion by offering future perspectives on the evolving treatment landscape in multiple myeloma, highlighting exciting developments and ongoing research.

Video content above is prompted by the following question:

  • What are your final thoughts regarding unmet needs and future perspectives for CAR T-cell therapy in relapsed/refractory multiple myeloma?
Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma

Tim Cortese
June 19th 2025
Article

Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Ariana Pelosci
June 16th 2025
Article

The MagnetisMM-6 trial results showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

Isatuximab Combination Significantly Sustains MRD Negativity in NDMM

Russ Conroy
June 16th 2025
Article

Low rates of early relapse in both arms of the phase 3 IsKia trial support the efficacy of carfilzomib in this newly diagnosed multiple myeloma setting.

Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

Ariana Pelosci
June 14th 2025
Article

Results of the PREDATOR-MRD trial found that daratumumab could help predict MRD response for patients with multiple myeloma.